Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
UOX
MCID: URT049
MIFTS: 26

Urate Oxidase, Pseudogene (UOX)

Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Urate Oxidase, Pseudogene

About this section

MalaCards integrated aliases for Urate Oxidase, Pseudogene:

Name: Urate Oxidase, Pseudogene 57 13
Uricase 57
Uox 57

External Ids:

OMIM 57 191540
Sources

Summaries for Urate Oxidase, Pseudogene

About this section
OMIM : 57 In most mammals, the activity of urate oxidase (EC 1.7.3.3) catalyzes the oxidation of uric acid to allantoin; humans and some primates lack this enzyme activity. The loss of urate oxidase in the human during primate evolution predisposes man to hyperuricemia, a metabolic disturbance that can lead to gouty arthritis and renal stones (summary by Wu et al., 1994). (191540)

MalaCards based summary : Urate Oxidase, Pseudogene, also known as uricase, is related to gout and hyperuricemia. An important gene associated with Urate Oxidase, Pseudogene is UOX (Urate Oxidase (Pseudogene)). The drugs Febuxostat and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and endothelial.

Sources

Related Diseases for Urate Oxidase, Pseudogene

About this section

Diseases related to Urate Oxidase, Pseudogene via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 16)
# Related Disease Score Top Affiliating Genes
1 gout 10.9
2 hyperuricemia 10.8
3 diabetes insipidus, nephrogenic, autosomal 10.2
4 lymphoma, hodgkin, classic 10.2
5 lymphoma, non-hodgkin, familial 10.2
6 diabetes insipidus 10.2
7 burkitt lymphoma 10.1
8 hepatocellular carcinoma 10.1
9 nephrolithiasis, calcium oxalate 10.1
10 wilms tumor 5 10.1
11 hyperglycemia 10.1
12 uremia 10.1
13 severe combined immunodeficiency 10.1
14 fatty liver disease 10.1
15 acute respiratory distress syndrome 10.1
16 rapidly involuting congenital hemangioma 10.1

Graphical network of the top 20 diseases related to Urate Oxidase, Pseudogene:



Diseases related to Urate Oxidase, Pseudogene
Sources

Symptoms & Phenotypes for Urate Oxidase, Pseudogene

About this section

Clinical features from OMIM:

191540
Sources

Drugs & Therapeutics for Urate Oxidase, Pseudogene

About this section

Drugs for Urate Oxidase, Pseudogene (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 48)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Febuxostat Approved Phase 4 144060-53-7 134018
2
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
3
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
4
Norethindrone Approved Phase 4 68-22-4 6230
5
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
6
Polyestradiol phosphate Approved Phase 4 28014-46-2
7
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
8
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
9
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
10
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
11
Uric acid Investigational Phase 4 69-93-2 1175
12 Tocotrienol Investigational Phase 4 6829-55-6
13 Antirheumatic Agents Phase 4
14 Antioxidants Phase 4
15 Protective Agents Phase 4
16 Pharmaceutical Solutions Phase 4
17 Angiotensinogen Phase 4
18 Giapreza Phase 4
19 Contraceptives, Oral Phase 4
20 Sodium Chloride Symporter Inhibitors Phase 4
21 Antihypertensive Agents Phase 4
22 Estrogens Phase 4
23 Progestins Phase 4
24 Natriuretic Agents Phase 4
25 HIV Protease Inhibitors Phase 4
26 Hormones Phase 4
27 diuretics Phase 4
28 Contraceptive Agents Phase 4
29
protease inhibitors Phase 4
30 Norethindrone Acetate Phase 4
31 Estradiol 17 beta-cypionate Phase 4
32 Angiotensin-Converting Enzyme Inhibitors Phase 4
33 Hormone Antagonists Phase 4
34 Estradiol 3-benzoate Phase 4
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
36 Antineoplastic Agents, Phytogenic Phase 4
37 insulin Phase 4
38 Silybin Phase 4
39 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
40 Tocopherols Phase 4
41 Insulin, Globin Zinc Phase 4
42 Tocotrienols Phase 4
43 Vitamins Phase 4
44 Lecithin Phase 4
45
Allopurinol Approved Phase 2 315-30-0 2094
46
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616 46835353
47
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
48
Rasburicase Approved, Investigational Phase 1 134774-45-1

Interventional clinical trials:

(show all 19)
# Name Status NCT ID Phase Drugs
1 Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS) Completed NCT01328769 Phase 4 Febuxostat;Placebo
2 Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women. Completed NCT03921736 Phase 4 Perindopril;Hydrochlorothiazide;Estracomb TTS
3 Metabolic and Vascular Effects of Silybin in Hypertensive Patients With High One-hour Post-load Plasma Glucose: a Single Arm Pilot Study Completed NCT03538327 Phase 4 Silybin
4 Randomized, Multicenter, Double-blind, Placebo-controlled Efficacy and Safety Study of 8 mg PEG-uricase in Two Dose Regimens in Hyperuricemic Subjects With Symptomatic Gout Completed NCT00325195 Phase 3
5 Multicenter, Open Label Extension Study of 8 mg PEG-uricase in Subjects Who Completed Protocols C0405 or C0406 for Symptomatic Gout Completed NCT01356498 Phase 3
6 A Phase II Multidose Study of Intravenous PEG-uricase in Patients With Refractory Gout Completed NCT00111657 Phase 2
7 An Open Label Phase II Multiple Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 Followed by Open Label Administration of SEL-037 in Subjects With Symptomatic Gout and Elevated Blood Uric Acid Completed NCT02959918 Phase 2 SEL-212;SEL-037;SVP-rapamycin (SEL-110)
8 A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Patients Refractory to Conventional Therapy Recruiting NCT03905512 Phase 2 SEL-212;SEL-037;SEL-110;KRYSTEXXA®
9 ULTRA-T2D Study: Uric Acid Lowering Trial in Youth Onset T2D Not yet recruiting NCT03899883 Phase 2 Pegloticase 8 MG/ML [Krystexxa]
10 A Cohort Dose-Escalation Phase 1 Study of Intramuscular Injection of Uricase-PEG 20 Unknown status NCT01038947 Phase 1
11 A Cohort Dose-Escalation Phase 1 Study of Intravenous Infusion of Uricase-PEG 20 Unknown status NCT01021241 Phase 1
12 An Open-Label, Sequential, Ascending Single-Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Study of an Intravenous Infusion of SEL-037 in Subjects With Elevated Blood Uric Acid Levels Completed NCT02464605 Phase 1
13 A Phase I Single Ascending Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 in Subjects With Elevated Blood Uric Acid Completed NCT02648269 Phase 1 SEL-110
14 The Relationship Between Uric Acid and Inflammatory Markers Completed NCT01323335 Phase 1 IV Uric Acid;IV Rasburicase
15 A Randomized, Double-blinded, Placebo-controlled, Single-dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SSS11 Administered Intravenously in Healthy Volunteers. Recruiting NCT03388515 Phase 1
16 An Open Label, Single-dose, Dose-increasing Study to Assess the Safety, Tolerability, PK and Preliminary PD of PEGylated Recombinant Candida Urate Oxidase (SSS11) for Injection in Chinese Healthy Adult Volunteers Not yet recruiting NCT04047394 Phase 1 PEGylated recombinant candida urate oxidase
17 Association of Maternal Uric Acid With Maternal Condition and Fetal Outcome in Pregnant Women With Hypertension Unknown status NCT01523327
18 Differential Effects of Uric Acid and Xanthine Oxidoreductase on Endothelial Function and Oxydative Stress Recruiting NCT03395977 Placebos;Febuxostat;Rasburicase
19 Paediatric Obesity and Cardiovascular Dysfunction: Searching for Early Markers of Damage Active, not recruiting NCT03169257

Search NIH Clinical Center for Urate Oxidase, Pseudogene

Sources

Genetic Tests for Urate Oxidase, Pseudogene

About this section
Sources

Anatomical Context for Urate Oxidase, Pseudogene

About this section

MalaCards organs/tissues related to Urate Oxidase, Pseudogene:

41
Liver, Kidney, Endothelial, Testes, Brain, Heart, Retina
Sources

Publications for Urate Oxidase, Pseudogene

About this section

Articles related to Urate Oxidase, Pseudogene:

(show top 50) (show all 1014)
# Title Authors PMID Year
1
Evolutionary history and metabolic insights of ancient mammalian uricases. 38 8
24550457 2014
2
Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. 38 8
8290593 1994
3
Structural analysis of the gene encoding rat uricase. 38 8
1783398 1991
4
Urate oxidase: primary structure and evolutionary implications. 38 8
2594778 1989
5
A human genomic sequence highly homologous to the 3'-untranslated region of rat uricase mRNA. 38 8
3178807 1988
6
Localization of the human urate oxidase gene (UOX) to 1p22. 8
1395718 1992
7
Human urate oxidase gene: cloning and partial sequence analysis reveal a stop codon within the fifth exon. 8
2403354 1990
8
Generation of cDNA probes directed by amino acid sequence: cloning of urate oxidase. 8
3344434 1988
9
A potential animal model for Lesch-Nyhan syndrome through introduction of HPRT mutations into mice. 8
3029599 1987
10
HPRT-deficient (Lesch-Nyhan) mouse embryos derived from germline colonization by cultured cells. 8
3821905 1987
11
Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? 8
13937884 1962
12
A ratiometric fluorescent probe for detection of uric acid based on the gold nanoclusters-quantum dots nanohybrid. 38
31176998 2019
13
Screening of single or combined administration of 9 probiotics to reduce ammonia emissions from laying hens. 38
30982063 2019
14
Application of cyclic voltammetry to analyse uric acid and reducing agents in commercial milks. 38
31151606 2019
15
Toxicity assessment of wearable wound sensor constituents on keratinocytes. 38
30928693 2019
16
Antioxidant capacities in various animal sera as measured with multiple free-radical scavenging method. 38
31272792 2019
17
Nanozymes: From New Concepts, Mechanisms, and Standards to Applications. 38
31276379 2019
18
Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout. 38
31079535 2019
19
Mouse models for human hyperuricaemia: a critical review. 38
31118497 2019
20
Serum Urate, Uricase, and Blood Pressure Control in Gout. 38
31079534 2019
21
Uricase grafted nanoconducting matrix based electrochemical biosensor for ultrafast uric acid detection in human serum samples. 38
30797811 2019
22
Fabrication of an efficient and sensitive colorimetric biosensor based on Uricase/ Th-MOF for uric acid sensing in biological samples. 38
31220726 2019
23
Structure-based design of a hyperthermostable AgUricase for hyperuricemia and gout therapy. 38
31253939 2019
24
A nanocomposite prepared from copper(II) and nitrogen-doped graphene quantum dots with peroxidase mimicking properties for chemiluminescent determination of uric acid. 38
31161235 2019
25
Uricase and Horseradish Peroxidase Hybrid CaHPO₄ Nanoflower Integrated with Transcutaneous Patches for Treatment of Hyperuricemia. 38
30890227 2019
26
Statistical media optimization for the production of clinical uricase from Bacillus subtilis strain SP6. 38
31193400 2019
27
Association between Serum Uric Acid Level with Presence and Severity of Coronary Artery Disease. 38
31311215 2019
28
Urate-lowering therapy alleviates atherosclerosis inflammatory response factors and neointimal lesions in a mouse model of induced carotid atherosclerosis. 38
30690853 2019
29
Uric acid analogue as a possible xenobiotic marker of uric acid transporter Urat1 in rats. 38
30826184 2019
30
Uric acid therapy for vasculoprotection in acute ischemic stroke. 38
31334357 2019
31
Advanced Colorimetric Paper Sensors Using Color Focusing Effect Based on Asymmetric Flow of Fluid. 38
30950270 2019
32
Potential Dangers of Serum Urate-Lowering Therapy. 38
30611833 2019
33
Nonenzymatic Serum Antioxidant Capacity in IBD and Its Association with the Severity of Bowel Inflammation and Corticosteroids Treatment. 38
30986917 2019
34
Pharmacological urate-lowering approaches in chronic kidney disease. 38
30769179 2019
35
Production and Characterization of Recombinant Wild Type Uricase from Indonesian Coelacanth (L. menadoensis) and Improvement of Its Thermostability by In Silico Rational Design and Disulphide Bridges Engineering. 38
30871218 2019
36
An electrochemical biosensor based on novel butylamine capped CZTS nanoparticles immobilized by uricase for uric acid detection. 38
30597431 2019
37
Antioxidant properties of citric acid interfere with the uricase-based measurement of circulating uric acid. 38
30447534 2019
38
A highly selective and sensitive colorimetric detection of uric acid in human serum based on MoS2-catalyzed oxidation TMB. 38
30542813 2019
39
Feeding-produced subchronic high plasma levels of uric acid improve behavioral dysfunction in 6-hydroxydopamine-induced mouse model of Parkinson's disease. 38
29847340 2019
40
Zwitterionic Hydrogels Based on a Degradable Disulfide Carboxybetaine Cross-Linker. 38
30119608 2019
41
Electrochemical Detection for Uric Acid Based on β-Lactoglobulin-Functionalized Multiwall Carbon Nanotubes Synthesis with PtNPs Nanocomposite. 38
30634585 2019
42
Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia. 38
30951542 2019
43
U-Shaped Association Between Serum Uric Acid Levels and Cognitive Functions in Patients with Type 2 Diabetes: A Cross-Sectional Study. 38
30958355 2019
44
Review of the Literature Examining the Association of Serum Uric Acid with Osteoporosis and Mechanistic Insights into Its Effect on Bone Metabolism. 38
30387405 2019
45
A Chromatin-Mimetic Nanomedicine for Therapeutic Tolerance Induction. 38
30412375 2018
46
A Case Report of Immunosuppressant Medication‒Associated Polyarticular Tophaceous Gout Successfully Treated Using the Polyethylene Glycol‒Conjugated Uricase Enzyme Pegloticase. 38
30577324 2018
47
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase. 38
30594229 2018
48
Investigation on uric acid biosensor model for enzyme layer thickness for the application of arthritis disease diagnosis. 38
29713461 2018
49
Enzymatic determination of uric acid using water-soluble CuInS/ZnS quantum dots as a fluorescent probe. 38
30291453 2018
50
Adaptive effect of sericin on hepatic mitochondrial conformation through its regulation of apoptosis, autophagy and energy maintenance: a proteomics approach. 38
30297713 2018
Sources

Variations for Urate Oxidase, Pseudogene

About this section
Sources

Expression for Urate Oxidase, Pseudogene

About this section
Search GEO for disease gene expression data for Urate Oxidase, Pseudogene.
Sources

Pathways for Urate Oxidase, Pseudogene

About this section
Sources

GO Terms for Urate Oxidase, Pseudogene

About this section
Sources

Sources for Urate Oxidase, Pseudogene

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....